|
122 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
12 Trials |
|
2436 News |
|
| «12345678910111213...4950» |
- | metformin / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal: Improving Fibrosis Outcomes With Metformin (clinicaltrials.gov) - Apr 17, 2018
P2, N=0, Withdrawn, Sponsor: Ottawa Hospital Research Institute
N=60 --> 0 | Trial completion date: Sep 2017 --> Apr 2018 | Suspended --> Withdrawn
- | Enrollment change: Early Antiviral Therapy for Critically Ill HIV Infected Patients (clinicaltrials.gov) - Apr 12, 2018
P4, N=115, Completed, Sponsor: Hospital Nossa Senhora da Conceicao
N=60 --> 0 | Trial completion date: Sep 2017 --> Apr 2018 | Suspended --> Withdrawn N=344 --> 115
- | Phase classification, HEOR: Medical Marijuana Use in HIV+ Patients Prospective Cohort Study (clinicaltrials.gov) - Apr 6, 2018
P, N=119, Completed, Sponsor: Wayne State University
N=344 --> 115 Phase classification: P=N/A --> P
- | Phase classification: Response to Standard HIV Treatment in Bamako, Mali (clinicaltrials.gov) - Apr 6, 2018
P, N=76, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P Phase classification: P=N/A --> P
- |||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Phase classification, Trial completion date, Trial primary completion date: A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication (clinicaltrials.gov) - Mar 31, 2018
P, N=99, Completed, Sponsor: Gilead Sciences
Phase classification: P=N/A --> P Phase classification: P=N/A --> P | Trial completion date: Jan 2017 --> Mar 2018 | Trial primary completion date: Jan 2017 --> Mar 2018
- | Trial completion, Phase classification: CN-PART: Chinese Network of Pediatric Antiretroviral Therapy (clinicaltrials.gov) - Mar 31, 2018
P, N=400, Completed, Sponsor: National Center for AIDS/STD Control and Prevention, China CDC
Phase classification: P=N/A --> P | Trial completion date: Jan 2017 --> Mar 2018 | Trial primary completion date: Jan 2017 --> Mar 2018 Recruiting --> Completed | Phase classification: PN/A --> P
- ||||||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA (clinicaltrials.gov) - Mar 27, 2018
P, N=64186, Completed, Sponsor: Gilead Sciences
Recruiting --> Completed | Phase classification: PN/A --> P Active, not recruiting --> Completed | Phase classification: PN/A --> P | N=400 --> 64186 | Trial completion date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2018
- | Trial completion, Trial completion date, Trial primary completion date: Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand (clinicaltrials.gov) - Mar 20, 2018
P=N/A, N=2816, Completed, Sponsor: Institut de Recherche pour le Developpement
Active, not recruiting --> Completed | Phase classification: PN/A --> P | N=400 --> 64186 | Trial completion date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Feb 2018 | Trial primary completion date: Sep 2020 --> Feb 2018
- | Phase classification, Adherence: DASH: Durability of Adherence in Self-Management of HIV (clinicaltrials.gov) - Mar 20, 2018
P=N/A, N=172, Completed, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Feb 2018 | Trial primary completion date: Sep 2020 --> Feb 2018 Phase classification: P3 --> P=N/A
- | Hiltonol (poly-ICLC) / Oncovir
Trial completion: Enhancement by Poly-ICLC During HIV-1 Infection (clinicaltrials.gov) - Mar 13, 2018
P1/2, N=15, Completed, Sponsor: Nina Bhardwaj
Phase classification: P3 --> P=N/A Active, not recruiting --> Completed
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents (clinicaltrials.gov) - Mar 9, 2018
P2/3, N=50, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | valacyclovir / Generic mfg.
Trial completion: Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals? (clinicaltrials.gov) - Mar 6, 2018
P3, N=202, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Stamaril (yellow fever vaccine) / Sanofi
Trial primary completion date: The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) - Mar 3, 2018
P3, N=71, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Nov 2017
- ||||||| Trial completion, Trial completion date: PRINCE2: Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (clinicaltrials.gov) - Mar 1, 2018
P3, N=160, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2017 --> Nov 2017 Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Jan 2018
- | Trial completion: Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients (clinicaltrials.gov) - Mar 1, 2018
P=N/A, N=614, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Jan 2018 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: INTESTIPAX: IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection (clinicaltrials.gov) - Feb 27, 2018
P=N/A, N=45, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Trial primary completion date: Jul 2017 --> Jul 2018 | Trial completion date: Jul 2018 --> Jul 2019
- | Trial completion date, Trial primary completion date: Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread? (clinicaltrials.gov) - Feb 27, 2018
P=N/A, N=0, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Jul 2017 --> Jul 2018 | Trial completion date: Jul 2018 --> Jul 2019 Trial primary completion date: Dec 2014 --> Feb 2018 | Trial completion date: Dec 2014 --> Feb 2018
- | Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: Healthy Options: Group Psychotherapy for HIV-positive Depressed Perinatal Women. (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=742, Completed, Sponsor: Harvard Medical School
Trial primary completion date: Dec 2014 --> Feb 2018 | Trial completion date: Dec 2014 --> Feb 2018 Active, not recruiting --> Completed | Initiation date: Jan 2014 --> Jul 2013 | Trial completion date: Mar 2018 --> Dec 2017 | Trial primary completion date: Feb 2018 --> Dec 2017
- |||| valacyclovir / Generic mfg.
Trial completion: VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies. (clinicaltrials.gov) - Feb 21, 2018
P4, N=73, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Initiation date: Jan 2014 --> Jul 2013 | Trial completion date: Mar 2018 --> Dec 2017 | Trial primary completion date: Feb 2018 --> Dec 2017 No longer recruiting --> Completed
- | Trial completion, Adherence: MedCHEC: Medications for Chronic HIV: Education and Collaboration (clinicaltrials.gov) - Feb 20, 2018
P=N/A, N=371, Completed, Sponsor: Boston University
No longer recruiting --> Completed Active, not recruiting --> Completed
- | bortezomib / Generic mfg.
Trial completion, Trial primary completion date: Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma (clinicaltrials.gov) - Feb 20, 2018
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2015
- | Trial completion: Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM) (clinicaltrials.gov) - Feb 15, 2018
P=N/A, N=856, Completed, Sponsor: Medical College of Wisconsin
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2015 Active, not recruiting --> Completed
- || emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion date, Trial primary completion date: A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA (clinicaltrials.gov) - Feb 14, 2018
P=N/A, N=400, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Jun 2018 | Trial completion date: Dec 2017 --> Jun 2018
- | Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
Trial initiation date, Trial termination: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - Feb 13, 2018
P2b, N=71, Terminated, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Dec 2017 --> Jun 2018 | Trial completion date: Dec 2017 --> Jun 2018 Initiation date: Apr 2013 --> Jul 2013 | Completed --> Terminated; The study was stopped early due to feasibility concerns.
- | Enrollment change: Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women (clinicaltrials.gov) - Feb 12, 2018
P=N/A, N=205, Active, not recruiting, Sponsor: FHI 360
Initiation date: Apr 2013 --> Jul 2013 | Completed --> Terminated; The study was stopped early due to feasibility concerns. N=166 --> 205
- ||| Trial completion, Phase classification: Reducing HIV Risks in African American Teens (clinicaltrials.gov) - Feb 1, 2018
P=N/A, N=1200, Completed, Sponsor: Education Development Center, Inc.
N=166 --> 205 Active, not recruiting --> Completed | Phase classification: P2 --> PN/A
- | Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
Trial completion, Enrollment change: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis (clinicaltrials.gov) - Feb 1, 2018
P2, N=104, Completed, Sponsor: PATH
Active, not recruiting --> Completed | Phase classification: P2 --> PN/A Active, not recruiting --> Completed | N=132 --> 104
- | Trial completion, Phase classification: Selective Exposure in HIV Prevention (clinicaltrials.gov) - Jan 17, 2018
P2, N=722, Completed, Sponsor: University of Illinois at Urbana-Champaign
Active, not recruiting --> Completed | N=132 --> 104 Recruiting --> Completed | Phase classification: P2/3 --> P2
- | dipyridamole / Generic mfg.
Trial completion, IO biomarker: Dipyridamole for Immune Activation in HIV (clinicaltrials.gov) - Jan 8, 2018
P1/2, N=40, Completed, Sponsor: Sharon Riddler
Recruiting --> Completed | Phase classification: P2/3 --> P2 Recruiting --> Completed
- | Trial completion, Gene therapy: Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial (clinicaltrials.gov) - Dec 27, 2017
P2, N=37, Completed, Sponsor: Janssen-Cilag Pty Ltd
Recruiting --> Completed Active, not recruiting --> Completed
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Trial primary completion date: An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis (clinicaltrials.gov) - Dec 21, 2017
P2, N=200, Completed, Sponsor: Westat
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Nov 2015
- | New trial: PUSH: Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART) (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=183, Completed, Sponsor: University of Washington
- | New trial: Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=1181, Completed, Sponsor: University of Pennsylvania
- | New trial, Adherence: A Commitment Device for Medication Adherence Among HIV Patients (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=110, Completed, Sponsor: National Bureau of Economic Research, Inc.
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg., lamivudine/zidovudine / Generic mfg.
New P2 trial, Combination therapy: Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV (clinicaltrials.gov) - Dec 19, 2017
P2, N=267, Completed, Sponsor: University of California, Los Angeles
- | Phase classification: Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=1181, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Nov 2015 Phase classification: P2 --> P=N/A
- | Phase classification, Enrollment change: Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=148, Completed, Sponsor: Johns Hopkins University
Phase classification: P2 --> P=N/A Phase classification: P3 --> P=N/A | N=387 --> 148
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion, Enrollment change: Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Dec 19, 2017
P2, N=16, Completed, Sponsor: University of Colorado, Denver
Phase classification: P3 --> P=N/A | N=387 --> 148 Active, not recruiting --> Completed | N=360 --> 16
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg., lamivudine/zidovudine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV (clinicaltrials.gov) - Dec 18, 2017
P2, N=267, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | N=360 --> 16 Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 | Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 | Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010
- | Enrollment change, Adherence: A Commitment Device for Medication Adherence Among HIV Patients (clinicaltrials.gov) - Dec 18, 2017
P=N/A, N=110, Completed, Sponsor: National Bureau of Economic Research, Inc.
Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 | Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 | Recruiting --> Completed | N=100 --> 267 | Trial primary completion date: Dec 2010 --> Jun 2010 N=39 --> 110
- | Phase classification: Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=662, Completed, Sponsor: University of Pennsylvania
N=39 --> 110 Phase classification: P2/3 --> P=N/A
- | atorvastatin / Generic mfg.
Trial completion, Enrollment change: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Dec 12, 2017
P4, N=5, Completed, Sponsor: University of Pennsylvania
Phase classification: P2/3 --> P=N/A Active, not recruiting --> Completed | N=15 --> 5
- | Phase classification: The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling (clinicaltrials.gov) - Dec 12, 2017
P=N/A, N=97, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | N=15 --> 5 Phase classification: P4 --> P=N/A
- | Trial completion: A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV (clinicaltrials.gov) - Dec 7, 2017
P=N/A, N=750, Completed, Sponsor: Nova Southeastern University
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed
- | Trial completion: Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women (clinicaltrials.gov) - Dec 5, 2017
P=N/A, N=148, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial termination: Development of Resistance Mutations in Pregnant HIV-positive (+) Women Following Perinatal Antiretroviral Therapy in Israel (clinicaltrials.gov) - Nov 28, 2017
P=N/A, N=50, Terminated, Sponsor: Hadassah Medical Organization
Recruiting --> Completed Recruiting --> Terminated; Difficulties in data collection
- || Rukobia (fostemsavir) / ViiV Healthcare
Trial primary completion date: HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections (clinicaltrials.gov) - Nov 20, 2017
P2b, N=254, Completed, Sponsor: ViiV Healthcare
Recruiting --> Terminated; Difficulties in data collection Trial primary completion date: May 2017 --> Feb 2013
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed, Enrollment change: PrEP-India: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India (clinicaltrials.gov) - Nov 17, 2017
P1, N=1325, Active, not recruiting, Sponsor: University of Manitoba
Trial primary completion date: May 2017 --> Feb 2013 Recruiting --> Active, not recruiting | N=2000 --> 1325
- || Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial completion: Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants (clinicaltrials.gov) - Nov 13, 2017
P2/3, N=31, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | N=2000 --> 1325 Active, not recruiting --> Completed
- | Enrollment closed, Phase classification: Asha II: Asha Improving Health and Nutrition of Indian Women With AIDS and Their Children (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=600, Active, not recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: P1/2 --> PN/A